Sector: Healthcare | Industry: Biotechnology & Medical Research |
Company Contact | |
Address: | c/o WeWork, 595 Burrard St. VANCOUVER BC V7X 1L4 |
Tel: | N/A |
Website: | https://www.sironabiochem.com |
IR: | See website |
Key People | ||
Howard Y Chairman of the Board, Chief Executive Officer, Founder | Christopher D. Hopton Chief Financial Officer, Director | Geraldine Deliencourt-Godefroy Chief Scientific Officer, Director |
Business Overview |
Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with proprietary platform developed at its laboratory facility in France. Through its wholly owned subsidiary TFChem S.A.R.L., the Company specializes in stabilizing carbohydrate molecules. The principal activities of the Company include development of cosmetic and pharmaceutical active ingredients. TFChem develops and markets its GlycoMim technology for pharmaceutical and biotechnology comp anies. TFChem's proprietary chemistry technology can be applied to the development of several pharmaceutical domains such as cancer, diabetes, pain and inflammation and cardio-vascular diseases. Its cosmetic therapeutic area includes skincare-dark spot corrector (Rx & OTC), cell preservation and repair (including keloid and scar therapy), skincare-anti aging/anti-wrinkle and skincare-cellulite treatment. It has developed an active ingredient, TFC-1067 for the treatment of Dyschromia (Dark spots on the skin). |
Financial Overview |
For the three months ended 31 January 2024, Sirona Biochem Corp revenues increased from C$0K to C$2K. Net loss increased 18% to C$732K. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Share-based payments increase from C$31K to C$188K (expense), Finance expense increase from C$1K to C$67K (expense). |
Reporting Currency: | Canadian Dollars |
Enterprise value: | $16.99M as of Jan 31, 2024 |
Annual revenue (TTM): | $0.04M as of Jan 31, 2024 |
EBITDA (TTM): | -$2.44M as of Jan 31, 2024 |
Net annual income (TTM): | -$2.65M as of Jan 31, 2024 |
Free cash flow (TTM): | -$2.08M as of Jan 31, 2024 |
Net Debt Last Fiscal Year: | $2.23M as of Jan 31, 2024 |
Shares outstanding: | 256,454,505 as of Apr 26, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |